Full Press Release Details
Inspira Preparing Production in Response to Spread of Respiratory
Ra'anana, Israel, January 10, 2025 -
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira" or the "Company"), a leader in life-support
technology innovation, announced today that it is preparing for a potential production ramp-up of its INSPIRA ART100 device. This
strategic readiness comes in light of the recent outbreak of human metapneumovirus (hMPV) in China, which has highlighted the growing
need for advanced respiratory care technologies globally.
Inspira is already in discussions with leading providers in affected
regions to evaluate demand for advance respiratory solutions and deployment of the INSPIRA ART100 device, ensuring rapid response
capabilities in case of increased demand.
As global health authorities monitor the hMPV outbreak, Inspira
believes that it is well-positioned to meet potential increased demand for advanced respiratory support systems. Inspira is working closely
with suppliers to secure necessary raw materials and components to meet potential demand spikes. The Company is following the hMPV situation
globally and working to adjust production plans as needed.
"While hMPV is not a new virus, and experts indicate the current
outbreak is part of normal seasonal patterns, Inspira believes in being prepared," said Dagi Ben-Noon, CEO of Inspira. "Our
increased production capacity will help ensure healthcare providers have access to vital respiratory care equipment should the need arise."
Inspira emphasizes that its preparedness measures are precautionary
and align with the Company's commitment to global health readiness. The Company will work closely with health authorities in affected
regions and adjust its plans based on the evolving situation.
InspiraTM Technologies Oxy B.H.N. Ltd.
Inspira Technologies is an innovative medical technology company in
the life support and respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA
ART), a groundbreaking device poised to revolutionize the $19 billion mechanical ventilation market. With 20 million intensive
care unit patients with acute respiratory failure each year, many of whom rely on mechanical ventilators, the INSPIRA ART offers a potential
alternative by elevating and stabilizing decreasing oxygen saturation levels in minutes without a ventilator, with patients being awake
during treatment. The INSPIRA ART is being equipped with a clip-on HYLA blood sensor, a real-time continuous blood monitoring technology,
aiming to alert physicians of changes in a patient's condition without the need for intermittent actual blood samples, aiming to support
physicians in making informed decisions.
In June and July 2024, respectively, the Company's INSPIRA ART100
system has obtained FDA 510(k) clearance for use in CBP procedures, along with the Israeli AMAR certification for both Extra-Corporeal
Membrane Oxygenation and Cardiopulmonary Bypass procedures.
The Company's other products and technologies, including the
INSPIRA ART also known as the INSPIRA ART500 or Gen 2, the INSPIRA Cardi-ART portable modular device, VORTX Oxygen
Delivery System, and HYLA blood sensor, are currently being designed and developed, and have not yet been tested or used in humans
nor approved by any regulatory entity.
For more information, please visit our corporate website at https://inspira-technologies.com.
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements
pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of
the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the growing
need for advanced respiratory care technologies, its ability to adjust its plans to rapidly respond in case of increased demand, the size
of its target market and that its technology is poised to revolutionize the $19 billion mechanical ventilation market. These
forward-looking statements and their implications are based solely on the current expectations of the Company's management and are
subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking
statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed
information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's
annual report on Form 20-F for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (the "SEC"),
which is available on the SEC's website at www.sec.gov.
Inspira Technologies - Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485
Copyright 2018-2025 Inspira Technologies OXY B.H.N. LTD., All